Abbott Laboratories 8-K
Executive pay
Change-in-control agreements extended through Dec. 31, 2028 for named executives except CEO Robert B. Ford, whose agreement expires Dec. 31, 2026.
Filed 2026-11-13 17:59 ET
- 5.02 Officer/director change
Summary
Executive change-in-control agreements extended. On 11/11/2026, Abbott extended the agreements for its named executive officers other than Chairman and CEO Robert B. Ford through 12/31/2028; Ford’s agreement expires on 12/31/2026.
Get emails when companies you follow file: email digest settings.
The summary is written by an AI model reading the filing.
Model 005 · prompt v192 · 2026-11-16 15:37:01Z